title: Cytotoxic effect of immunoconjugate composed of glucose-oxidase coupled to an anti-ganglioside (GD2) antibody on spheroids.
abstract: As a new treatment protocol for neuroblastoma, the chimeric (human/mouse) antiganglioside GD2 antibody chl4.18 is being clinically tested. To improve the therapeutic effect of the antibody alone, we are currently investigating the cytotoxicity of glucose-oxidase coupled to the antibody chl4.18 on spheroids of the neuroblastoma cell line SK-N-LO. The cytotoxic effect of glucose-oxidase is achieved by the production of hydrogenperoxide (H2O2) and probably by the following reaction of H2O2 with iron to form hydrogen radicals (OH.). The cytotoxicity of glucose-oxidase was measured by two viability tests (MTT and WST 1). After a 4 hour treatment of the spheroids with the immunoconjugate, a reduction of viability to 50% (MTT-test) and 25% (WST 1-test), respectively, was obtained. The difference between the results of these two tests, might be explained by the different measurement protocols.
authors.affiliation: Nuklearmedizinische Klinik der Technischen Universität München, Germany.
authors.forename: P
authors.initials: P
authors.lastname: Heiss
authors.forename: S
authors.initials: S
authors.lastname: Bernatz
authors.forename: G
authors.initials: G
authors.lastname: Bruchelt
authors.forename: R
authors.initials: R
authors.lastname: Senekowitsch-Schmidtke
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D005732:Gangliosides / Q000276:immunology*; D005949:Glucose Oxidase / Q000627:therapeutic use*; D006801:Humans; D018796:Immunoconjugates / Q000627:therapeutic use*; D009447:Neuroblastoma / Q000473:pathology / Q000628:therapy*; D018874:Spheroids, Cellular; D014407:Tumor Cells, Cultured
chemical_list: D000911:Antibodies, Monoclonal; D005732:Gangliosides; D018796:Immunoconjugates; C019403:ganglioside, GD2; D005949:Glucose Oxidase